Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 24.34 |
---|---|
High | 24.76 |
Low | 23.53 |
Bid | 24.47 |
Offer | 24.48 |
Previous close | 24.33 |
Average volume | 2.73m |
---|---|
Shares outstanding | 985.69m |
Free float | 686.82m |
P/E (TTM) | -- |
Market cap | 20.84bn CNY |
EPS (TTM) | -1.96 CNY |
Data delayed at least 15 minutes, as of Sep 19 2024.
More ▼
- Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates
- Junshi Biosciences Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma
- Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab
- Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer
- Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint
- Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
- Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates
More ▼